| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Departments of Pediatrics and Neurology (Dr. Graf), Psychiatry and Behavioral Sciences (Drs. Unis, Yates, and Sulzbacher), Genetics (Dr. Dinulos), Laboratory Medicine (Dr. Jack and Ms. Dugaw), Medicine (Ms. Paddock), and Biochemistry (Dr. Parson), University of Washington, Seattle.
Address correspondence and reprint requests to Dr. William D. Graf, The ACCORD Foundation, 1407 116th Avenue NE, Suite 106, Bellevue, WA 98004; e-mail: wgraf{at}accordfoundation.org
Objective:— To investigate catecholamine phenotypes and the effects of a tyrosine hydroxylase inhibitor in individuals with the 22q11.2 deletion syndrome and low-activity catechol-O-methyltransferase (COMT).
Background:— Many persons with the 22q11.2 deletion syndrome suffer severe disability from a characteristic ultrarapid-cycling bipolar disorder and associated "affective storms." One etiologic hypothesis for this condition is that deletion of the COMT gene from one chromosome 22 results in increased catecholamine neurotransmission, particularly if the undeleted chromosome 22 encodes a variant of COMT with low activity.
Methods:— In a preliminary study, plasma, urine, and CSF catecholamines and catecholamine metabolites were measured in four teenage patients with a neuropsychiatric condition associated with 22q11.2 deletion and the low-activity COMT polymorphism on the nondeleted chromosome. In these four patients, and an additional institutionalized adult with the condition, an uncontrolled, open-label trial of metyrosine was administered in an attempt to lower catecholamine production and to alleviate symptoms.
Results:— Mild elevations of baseline CSF homovanillic acid (HVA) were found in three of four patients and a moderate reduction in CSF HVA after metyrosine treatment in the patient with the highest pretreatment concentration. The course of the five patients during the clinical trial is described.
Conclusions:— In patients with the 22q11.2 deletion syndrome and low-activity COMT, controlled studies of pharmacologic agents that decrease catecholamine production, block presynaptic catecholamine storage, or enhance S-adenosylmethionine, the cosubstrate of COMT, are warranted.
This article has been cited by other articles:
|
|
 |
|
  C. E. Bearden, A. F. Jawad, D. R. Lynch, S. Sokol, S. J. Kanes, D. M. McDonald-McGinn, S. C. Saitta, S. E. Harris, E. Moss, P. P. Wang, et al. Effects of a Functional COMT Polymorphism on Prefrontal Cognitive Function in Patients With 22q11.2 Deletion Syndrome Am J Psychiatry, September 1, 2004; 161(9): 1700 - 1702. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. J. H. Cotton, B. Stoddard, and W. W. Parson Oxidative Inhibition of Human Soluble Catechol-O-methyltransferase J. Biol. Chem., May 28, 2004; 279(22): 23710 - 23718. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Bassett, E. W.C. Chow, P. AbdelMalik, M. Gheorghiu, J. Husted, and R. Weksberg The Schizophrenia Phenotype in 22q11 Deletion Syndrome Am J Psychiatry, September 1, 2003; 160(9): 1580 - 1586. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Disease Mechanisms in Neuroscience Neuroscientist, December 1, 2001; 7(6): 478 - 479. [PDF]
|
|
|
|
 |
|
 A. K. Percy and C. B. Nemeroff Chromosome 22q and the mind-brain interface: Bedside to bench to bedside Neurology, August 14, 2001; 57(3): 377 - 378. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
